113 related articles for article (PubMed ID: 25040195)
21. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
[TBL] [Abstract][Full Text] [Related]
22. Prevention of CNS relapse in diffuse large B-cell lymphoma.
Kridel R; Dietrich PY
Lancet Oncol; 2011 Dec; 12(13):1258-66. PubMed ID: 21933751
[TBL] [Abstract][Full Text] [Related]
23. [Isolated central nervous system relapse of diffuse large B-cell lymphoma in the era of immunochemotherapy].
Krmek DZ; Ljubić N; Vrbanić L
Acta Med Croatica; 2012 Dec; 66(5):403-7. PubMed ID: 23814970
[TBL] [Abstract][Full Text] [Related]
24. Statistical and trial design considerations in central nervous system prophylaxis studies.
Smith JA; Glantz M
Semin Oncol; 2009 Aug; 36(4 Suppl 2):S69-76. PubMed ID: 19660685
[TBL] [Abstract][Full Text] [Related]
25. [Central nervous system involvement in diffuse large B-cell lymphoma: prevention and treatment].
Zhou D; Zhang W
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):284-5. PubMed ID: 24759011
[No Abstract] [Full Text] [Related]
26. The science of prevention: novel strategies for and new insights into central nervous system prophylaxis in patients with cancer.
Glantz M; Recht L
Semin Oncol; 2009 Aug; 36(4 Suppl 2):S1. PubMed ID: 19660678
[No Abstract] [Full Text] [Related]
27. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
[TBL] [Abstract][Full Text] [Related]
28. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Shimada K
Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
[TBL] [Abstract][Full Text] [Related]
29. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
30. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-hodgkin lymphoma.
Desai J; Mitnick RJ; Henry DH; Llena J; Sparano JA
Cancer; 1999 Nov; 86(9):1840-7. PubMed ID: 10547559
[TBL] [Abstract][Full Text] [Related]
31. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.
Kansara R; Villa D; Gerrie AS; Klasa R; Shenkier T; Scott DW; Slack GW; Gascoyne RD; Connors JM; Sehn LH; Savage KJ
Br J Haematol; 2017 Nov; 179(3):508-510. PubMed ID: 27443424
[No Abstract] [Full Text] [Related]
32. Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how?
Korfel A
Curr Opin Oncol; 2011 Sep; 23(5):436-40. PubMed ID: 21760506
[TBL] [Abstract][Full Text] [Related]
33. [Primary testicular lymphoma].
Motyčková M; Vosáhlová V; Belada D; Šimkovič M; Žák P
Vnitr Lek; 2017; 63(6):415-422. PubMed ID: 28840738
[TBL] [Abstract][Full Text] [Related]
34. The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma.
Mitrovic Z; Bast M; Bierman PJ; Bociek RG; Vose JM; Chan WC; Armitage JO
Br J Haematol; 2012 May; 157(3):401-3. PubMed ID: 22224728
[No Abstract] [Full Text] [Related]
35. High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.
Cheah CY; Joske D; Cull G; Gilbertson M; Opat SS; Tam CS; Wirth A; Seymour JF
Br J Haematol; 2017 Sep; 178(6):991-994. PubMed ID: 27470657
[No Abstract] [Full Text] [Related]
36. Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers.
Ryan GF; Roos DR; Seymour JF
Clin Lymphoma Myeloma; 2006 Jan; 6(4):337-41. PubMed ID: 16507213
[TBL] [Abstract][Full Text] [Related]
37. CNS prophylaxis in lymphoma: who to target and what therapy to use.
Hill QA; Owen RG
Blood Rev; 2006 Nov; 20(6):319-32. PubMed ID: 16884838
[TBL] [Abstract][Full Text] [Related]
38. A case of primary cardiac lymphoma showing isolated central nervous system relapse.
Jung YH; Woo IS; Ko YJ; Lee JH; Lim JW; Han CW
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e31-3. PubMed ID: 24220617
[No Abstract] [Full Text] [Related]
39. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
40. Secondary central nervous system lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Int J Hematol; 2006 Aug; 84(2):128-35. PubMed ID: 16926134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
